Sarasin & Partners LLP Sells 579,388 Shares of Zoetis Inc. $ZTS

Sarasin & Partners LLP lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 35.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,070,558 shares of the company’s stock after selling 579,388 shares during the quarter. Sarasin & Partners LLP owned about 0.24% of Zoetis worth $134,698,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of Zoetis in the 2nd quarter worth approximately $809,491,000. Diamond Hill Capital Management Inc. purchased a new position in Zoetis during the third quarter valued at $394,010,000. Nordea Investment Management AB raised its stake in Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after buying an additional 2,179,578 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock worth $394,746,000 after acquiring an additional 1,227,085 shares in the last quarter. Finally, Corient Private Wealth LLC boosted its holdings in Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after acquiring an additional 1,191,840 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.5%

Zoetis stock opened at $115.43 on Friday. Zoetis Inc. has a one year low of $114.36 and a one year high of $172.23. The stock has a fifty day moving average of $124.35 and a 200 day moving average of $130.44. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock has a market cap of $48.73 billion, a PE ratio of 19.17, a price-to-earnings-growth ratio of 1.77 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same period last year, the firm posted $1.40 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Weiss Ratings raised shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, March 12th. HSBC set a $140.00 price objective on shares of Zoetis in a research note on Wednesday, December 10th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, BTIG Research reiterated a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Six analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.